^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    NUV-868

    i
    Associations
    News

    Trials

    Company:
    Nuvation Bio
    Drug class:
    BRD4 inhibitor, BET-BD2 inhibitor
    Related drugs:
    Associations
    News

    Trials

    Apply
    NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors (NCT05252390)
    Phase 1/2
    Nuvation Bio Inc.
    Recruiting
    Last update posted :
    05/29/2024
    Initiation :
    03/29/2022
    Primary completion :
    06/01/2026
    Completion :
    11/01/2026
    BRCA
    |
    HRD • BRCA mutation
    |
    Lynparza (olaparib) • Xtandi (enzalutamide) • NUV-868